Genezen, a gene therapy contract development and manufacturing organization, has announced a strategic partnership with The Charlotte & Gwenyth Gray Foundation to Cure Batten Disease. This collaboration is designed to advance a promising CLN6 gene therapy into a Phase 1/2 clinical trial, offering renewed hope for children affected by this rare neurodegenerative disorder.
CLN6 Batten disease currently has no approved therapies, making the rapid development of potential treatments a critical priority. Utilizing its advanced viral vector manufacturing platform and regulatory expertise, Genezen has supported the swift progression of the therapy from proof of concept to Good Manufacturing Practice (GMP) clinical supply. The partnership reflects a streamlined model for advancing ultra-rare disease programs, emphasizing efficiency and scalability.
The collaboration involved direct engagement with the FDA to expedite the regulatory pathway to the clinic. By combining regulatory insight with a flexible, platform-based manufacturing approach, the team successfully accelerated the program's timeline. This initiative underscores the vital role of parent-led foundations in driving research and development for rare diseases, demonstrating how targeted funding and advocacy can catalyze significant scientific advancements.
The Gray Foundation, founded by parents committed to finding a cure for their daughters, continues to champion efforts to improve the lives of children impacted by Batten disease. The advancement of this CLN6 gene therapy into clinical trials represents a major milestone in the ongoing quest to develop effective, life-saving treatments for this devastating condition.
Medical Disclaimer: This information is for educational purposes only and does not constitute medical advice. Genetic testing and clinical management should be performed by qualified healthcare professionals.